glp 1 fda approved How FDA's Action Against Non-FDA-Approved GLP-1 Products Affects the competitive Landscape πNew GLP-1 pill gets FDA
Description
The STEP trial program demonstrated substantial weight reductions with many participants achieving losses approaching those seen with metabolic surgery
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression

A previous Phase 2 trial in 255 patients with Parkinsons disease suggested pegsebrenatide may slow the progression of motor dysfunction, with the most pronounced effects in patients younger than 60

doi: 10.1007/s00125-009-1532-3

In another trial, higher levels of PYY 3-36 were also observed relative to baseline after 16 weeks of treatment with liraglutide 3.0 mg [34]

Ma YL, Kong CY, Guo Z, Wang MY, Wang P, Liu FY, et al